
Charting a newer, faster path for the U.S. in first-in-human trials
As China raises the bar on First-in-Human trials, the U.S. faces the need to adapt, fast. The BioCentury Forum convenes 50 leaders from across the biopharma ecosystem for one day of candid, Chatham House debate on the policy and regulatory changes that can make the U.S. remain competitive and meet drugmakers needs in first-in-human trials.
Event Highlights:
Attendance is by invitation only.
To learn more, email conferences@biocentury.com